OPEN END TURBO PUT WARRANT - ASTRAZENECA ADR | Market Closed - Börse Stuttgart 04:52:15 2024-06-26 am EDT | ||
| 3.07 EUR | -2.23% |
|
| Current month | -5.42% | ||
| 1 month | -3.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 3.07 | -2.23% |
| 24-06-25 | 3.14 | -1.88% |
| 24-06-24 | 3.2 | -1.23% |
| 24-06-21 | 3.24 | +0.62% |
| 24-06-20 | 3.22 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 04:52 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5MH9 |
| ISIN | DE000UM5MH91 |
| Date issued | 2024-05-14 |
| Strike | 112.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.41 € |
|---|---|
| Lowest since issue | 2.97 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.04%
- Stock Market
- Certificates
- Certificat
